Cargando…
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation
Glioblastoma patients have a poor prognosis mainly due to temozolomide (TMZ) resistance. NRF2 is an important transcript factor involved in chemotherapy resistance due to its protective role in the transcription of genes involved in cellular detoxification and prevention of cell death processes, suc...
Autores principales: | de Souza, I., Monteiro, L. K. S., Guedes, C. B., Silva, M. M., Andrade-Tomaz, M., Contieri, B., Latancia, M. T., Mendes, D., Porchia, B. F. M. M., Lazarini, M., Gomes, L. R., Rocha, C. R. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270336/ https://www.ncbi.nlm.nih.gov/pubmed/35803910 http://dx.doi.org/10.1038/s41419-022-05044-9 |
Ejemplares similares
-
Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
por: Bagnoli, Marina, et al.
Publicado: (2013) -
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
por: Almeida Lima, Karoline, et al.
Publicado: (2023) -
Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014) -
Functional Expression of Multidrug Resistance Protein 4
MRP4/ABCC4
por: Hardy, David, et al.
Publicado: (2019) -
Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness
por: Sahores, A., et al.
Publicado: (2020)